<DOC>
	<DOCNO>NCT02416999</DOCNO>
	<brief_summary>This study evaluate effectiveness ultra-low dose Bevacizumab plus Temozolomide recurrent high-grade glioma .</brief_summary>
	<brief_title>Ultra-low Dose Bevacizumab Plus Temozolomide Recurrent High-grade Gliomas</brief_title>
	<detailed_description>This trial aim evaluate effectiveness ultra-low dose Bevacizumab plus Temozolomide recurrent high-grade glioma . And , trial approve medical ethic committee Hebei Yanda Hospital.Researchers conduct thsi trial 2015/05 2018/05 , 30 recurrent high-grade glioma patient recruit . Patients recruit get treatment ultra-low dose Bevacizumab plus Temozolomide ether Hebei Yanda Hospital Beijing Tiantan hospital , get follow-ups clinician .</detailed_description>
	<mesh_term>Glioma</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<criteria>High grade glioma diagnose postoperation pathological method , show relapse . Before included , patient need imageological examination , diameter contrast enhance area big 1cm , PET MRS result show positive feature . The age patient 18 year old 70 year old . The condition patient permit treatment ultralow dose Bevacizumab plus Temozolomide . The patient informed consent , willing join research . The diagnosis recurrent highgrade glioma . The diagnosis highgrade glioma establish pathological method . The result imageological examination meet standard include . The age patient meet requirement research . The condition patient permit treatment ultralow dose Bevacizumab plus Temozolomide . There condition clinician believe treatment ultralow dose Bevacizumab plus Temozolomide appropriate patient . The patient willing join research .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>glioma</keyword>
	<keyword>high-grade glioma</keyword>
</DOC>